Compare Noble Corporation plc (NE) vs ResMed Inc. (RMD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Noble Corporation plc vs ResMed Inc. — how do they compare? Noble Corporation plc trades at $42.36 (market cap $6.73B), while ResMed Inc. trades at $230.05 (market cap $31.89B). The key difference: ResMed Inc. is far larger — about 4.7× Noble Corporation plc's market cap, and Noble Corporation plc pays the higher dividend (4.74%). Which is the better fit depends on your goals — on Pluang, investors hold Noble Corporation plc for 26 Days and ResMed Inc. for 51 Days on average.
| NE | RMD | |
|---|---|---|
Market Cap | $6.73B | $31.89B |
Volume | 1,027,635 | 618,314 |
Sector | Energy | Health |
52-Week High | $54.37 | $275.96 |
52-Week Low | $26.70 | $182.82 |
Typical Hold Time | 26 Days | 51 Days |
Enterprise Value | $8.16B | $31.24B |
Dividend Yield | 4.74% | 1.16% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Noble Corporation (NE) trades at $42.15, up 2.88% today, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company reported $3.29B revenue for 2025 with 6.59% net margin, though 2026 projections show declining revenue and profitability. Recent news includes a long-term drilling contract with Tullow in Ghana, providing operational visibility into 2027.
The stock faces headwinds from declining earnings momentum and ongoing legal investigations, offset by positive analyst sentiment with a $52 consensus target representing 23% upside. Key risks include execution challenges in a volatile energy market and potential legal liabilities from the Pomerantz investigation announced September 2026.
ResMed (RMD) trades at $226.73, up 0.33% today, with a bullish technical signal from moving averages and a neutral RSI. The company reported strong earnings beats in recent quarters, with Q3 2026 results pending. Revenue grew to $5.15 billion in 2025, with a net income margin of 26.94%, while cash flow from operations reached $1.75 billion. Recent news highlights an upcoming Q1 2027 earnings report and management's focus on 12%-14% EPS growth driven by demand in sleep therapy.
The outlook for RMD is positive, supported by robust fundamentals and analyst consensus, though risks include competitive pressures and ongoing legal investigations. Upside potential exists with a consensus price target of $242.70, representing a 7% increase from current levels, but investors should monitor execution against growth targets and market share dynamics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Noble Corporation plc
Noble Corporation plc is a leading offshore drilling contractor for the oil and gas industry. The company owns and operates a high-specification fleet of mobile offshore drilling units, including drillships and semi-submersibles, that are used for exploration and production activities in deepwater and harsh environments worldwide. Noble focuses on providing safe, efficient, and reliable drilling services to major and independent oil and gas companies globally.
Read more on NE →About ResMed Inc.
ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.
Read more on RMD →
